REACT Neuro

REACT Neuro operates at the intersection of digital health, medical devices, neurotechnology, and cognitive assessment. Its differentiation is the combination of immersive virtual-reality tasks with passive behavioral and physiological measurements, rather than relying only on conventional questionnaires or isolated cognitive tests. The platform is designed to assess brain health and mental performance using signals such as eye movements, pupil responses, voice, and body movements, while the company’s RETINA technology provides a more specific technical foundation for multimodal measurement. The portfolio spans at-home assessment, clinical use, research, and senior-living settings, giving the company several potential deployment contexts. As a result, REACT Neuro’s competitive position is best characterized as a specialized, research-led digital neurocognitive platform rather than a demonstrably scaled market leader. Its multidisciplinary expertise across neuroscience, neuropsychology, neurosurgery, artificial intelligence, aging, Alzheimer’s disease, traumatic brain injury, and concussion is a meaningful differentiator, but the extent of adoption remains unclear.

REACT Neuro was founded in 2018 and lists a small team of approximately 11 to 50 employees, with four current positions represented in company records. The February 2019 acquisition by DRADS Capital was an early structural inflection point, followed by PharmStars’ non-equity assistance on July 12, 2022. The company’s development trajectory appears focused on converting multidisciplinary neuroscience research into deployable assessment products: a VR and machine-learning platform, a user-facing app, and purpose-specific headsets for senior living, clinics, and research environments. Its two granted patents and RETINA technology indicate investment in proprietary measurement methods, particularly around eye, pupil, and body-movement signals.